Medical Condition News

RSS

Merlin protein controls adult cell activity to cause liver cancer

A protein known to be involved in a rare hereditary cancer syndrome may have a role in the regulation of liver stem cells and the development of liver cancer. In the August 15 issue of Genes & Development, a Massachusetts General Hospital (MGH) research team describes finding that the protein called merlin, encoded by the NF2 (neurofibromatosis type 2) gene, controls the activity of adult stem cells that give rise to the two major types of liver cells.

13 Aug 2010

Research identifies intracellular mechanism for altering blood vessels permeability for tumours treatment

Dr. Jean-Philippe Gratton, Director of the Endothelial cell biology research unit at the Institut de recherches cliniques de Montr-al (IRCM), identifies a new intracellular mechanism responsible for modulating vascular permeability: the nitrosylation of beta-catenin protein by nitric oxide. This scientific breakthrough could have a possible impact on the treatment of cancerous tumours by altering the permeability of the blood vessels irrigating them. Dr. Gratton's team will publish the results of its research tomorrow in the scientific journal Molecular Cell.

13 Aug 2010

FDA grants new 510(k) clearance for Fenwal's Amicus blood cell separator

Fenwal Inc., a global medical technology company focused on improving blood collection, separation, safety and availability, announced today that the U.S. Food and Drug Administration has granted Fenwal a new 510(k) clearance for its Amicus® blood cell separator.

13 Aug 2010

Interbots to provide robot based therapy for autistic children

Interbots, Inc., a high-tech spin-off company associated with the Carnegie Mellon University Entertainment Technology Center has teamed up with the Autism Center of Pittsburgh to provide innovative robot-based therapy for children with autism.The program, "Character Therapy," through the use of the Interbot robot "Popchilla" will test the ability of children with autism with limited or no verbal skills.

13 Aug 2010

FDA grants LifeCycle Pharma SPA for LCP-Tacro pivotal Phase 3 study in 'de novo' kidney transplant patients

LifeCycle Pharma A/S today announced receipt of agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment of its pivotal Phase 3 study, Study 3002, for LCP-Tacro in patients, who have just received a kidney transplant.

12 Aug 2010

Fast food outlets can provide statin drugs to help customers neutralise heart disease: Researchers

Fast food outlets could provide statin drugs free of charge so that customers can neutralise the heart disease dangers of fatty food, researchers at Imperial College London suggest in a new study published this week.

12 Aug 2010

Halozyme Therapeutics granted U.S. patent for recombinant human hyaluronidase enzyme platform

Halozyme Therapeutics, Inc. today announced the issuance of U.S. Patent No. 7,767,429 claiming its proprietary recombinant human hyaluronidase enzyme platform (rHuPH20). Claims to the human PH20 glycoprotein, PEGylated variants, the glycoprotein produced by recombinant methods, and pharmaceutical compositions with other agents, including antibodies, insulins, cytokines, anti-infectives and additional therapeutic classes were awarded in the '429 patent. Additional claims are in prosecution.

12 Aug 2010

Interleukin Genetics, University of Michigan to conduct landmark clinical study on periodontal disease

Interleukin Genetics, Inc. announced today that the Company has signed an agreement with the University of Michigan to conduct a landmark clinical study on risk factors predictive of periodontal disease progression to tooth loss using a new version of Interleukin Genetics' PST genetic test.

12 Aug 2010

Study offers clues to potential treatments for preserving, restoring insulin-producing cells

In type 1 diabetes, the body relentlessly attacks and destroys its own insulin-producing pancreatic beta cells. But a study by Joslin Diabetes Center scientists now has firmly established that some of these cells endure for many decades in a small group of people with the disease—offering clues to potential treatments for preserving and even restoring the crucial cell population.

12 Aug 2010

Scientists awarded $348,037 to study causes, effects of hypoxia in Green Bay

Scientists researching the causes and effects of hypoxia in Green Bay, part of Lake Michigan, Wisc., have been awarded $348,037 for the first year of an anticipated four-year $1,367,300 project through NOAA's Coastal Hypoxia Research Program. Hypoxia within Green Bay has been a problem for decades, and recent evidence suggests that it may be worsening, with the potential for "dead zones" and fish kills to become both more frequent and more extensive with a changing climate.

12 Aug 2010

FDA advisory committee votes in favor of Ezogabine

The U.S. Food and Drug Administration advisory committee voted unanimously that clinical studies had provided substantial evidence of the effectiveness of Ezogabine (known as Retigabine outside of the U.S.) as adjunctive treatment for adults with partial-onset seizures.

12 Aug 2010

NYBC calls for blood donations

New York Blood Center, serving more than 20 million people in New York City, Long Island, the Hudson Valley, New Jersey, and parts of Connecticut and Pennsylvania, calls upon the communities it serves to remember your neighbors during this slow, late summer period for blood donations – and schedule a donation appointment or consider sponsoring a blood drive, because patients' needs do not take a summer break.

12 Aug 2010

Pelleve Wrinkle Reduction System launched across U.S.

Pelleve, the revolutionary skin tightening system for nonablative skin rejuvenation, is now available through dermatologists, plastic surgeons, medspas and cosmetic surgery clinics across the country.

12 Aug 2010

AVEO achieves enrollment target for tivozanib global Phase 3 clinical trial in advanced renal cell carcinoma

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has achieved its enrollment target for TIVO-1, its global Phase 3 clinical trial for its oral, triple VEGF receptor inhibitor, tivozanib, in patients with advanced renal cell carcinoma. In February of this year, AVEO initiated enrollment in TIVO-1, and has successfully reached the target enrollment of 500 patients.

12 Aug 2010

Eastern Pennsylvania Sudden Cardiac Arrest Association launches response team with Amish community

Underscoring that a sudden cardiac arrest emergency requires quick response and that automated external defibrillators are easy to use, the Eastern Pennsylvania Chapter of the Sudden Cardiac Arrest Association has launched a unique community response team with the Amish community of Lancaster County, Pennsylvania, at the center of a broad program that will deploy AEDs in public locations, schools and even on horse and buggies and Amish farms to protect the community's residents and visitors from the nation's leading cause of death.

12 Aug 2010

NAMI calls for $20 billion relief fund to cover mental health needs resulting from oil spill

The National Alliance on Mental Illness has called on Kenneth Feinberg, the independent claims administrator for the $20 billion relief fund created by BP Oil Company, to cover mental health needs resulting from the company's massive oil spill in the Gulf of Mexico.

12 Aug 2010

Researchers suggest Hsp70 can reverse Diabetic peripheral neuropathy

Researchers have been able to use a common chaperone protein, Hsp70, to reverse the loss of function in the nerves of mice with diabetes.Writing in ASN NEURO, Michael J. Urban and colleagues at the University of Kansas suggest that Hsp70 could be used in the future to cure the loss of feeling in the limbs that afflicts many diabetics.

12 Aug 2010

Pathway's drug development milestone triggers $4.5M tranche of Series A private equity placement

Pathway Therapeutics, a drug discovery and development company founded in New Zealand, announced that it has met an important drug development milestone triggering a US$4.5 million fourth tranche of its Series A private equity placement. The financing was led by GBS Venture Partners, Australia and CM Capital Investments, Australia with co-investors the Breast Cancer Research Trust, the Trans-Tasman Commercialisation Fund, and the New Zealand Venture Investment Firm.

12 Aug 2010

25% of stroke patients stop taking prevention medication within 3 months

At least a quarter of patients who have suffered a stroke stop taking one or more of their prescribed stroke prevention medications within the first three months after being hospitalized - when the chance of having another stroke is highest - according to a new study by researchers at Wake Forest University Baptist Medical Center and colleagues.

12 Aug 2010

Early administration of TXA reduces death from bleeding without increase in complications: Study

If recently injured patients with serious bleeding were to receive a cheap, widely available and easily administered drug to help their blood to clot, tens of thousands of lives could be saved every year, according to a paper published on-line today by The Lancet.

12 Aug 2010

Medical Condition News

Merlin protein controls adult cell activity to cause liver cancer

Research identifies intracellular mechanism for altering blood vessels permeability for tumours treatment

FDA grants new 510(k) clearance for Fenwal's Amicus blood cell separator

Interbots to provide robot based therapy for autistic children

FDA grants LifeCycle Pharma SPA for LCP-Tacro pivotal Phase 3 study in 'de novo' kidney transplant patients

Fast food outlets can provide statin drugs to help customers neutralise heart disease: Researchers

Halozyme Therapeutics granted U.S. patent for recombinant human hyaluronidase enzyme platform

Interleukin Genetics, University of Michigan to conduct landmark clinical study on periodontal disease

Study offers clues to potential treatments for preserving, restoring insulin-producing cells

Scientists awarded $348,037 to study causes, effects of hypoxia in Green Bay

FDA advisory committee votes in favor of Ezogabine

NYBC calls for blood donations

Pelleve Wrinkle Reduction System launched across U.S.

AVEO achieves enrollment target for tivozanib global Phase 3 clinical trial in advanced renal cell carcinoma

Eastern Pennsylvania Sudden Cardiac Arrest Association launches response team with Amish community

NAMI calls for $20 billion relief fund to cover mental health needs resulting from oil spill

Researchers suggest Hsp70 can reverse Diabetic peripheral neuropathy

Pathway's drug development milestone triggers $4.5M tranche of Series A private equity placement

25% of stroke patients stop taking prevention medication within 3 months

Early administration of TXA reduces death from bleeding without increase in complications: Study

The evolution of OCT for retinal imaging and disease intervention

Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation

Prof. Dr. Kristina Kusche-Vihrog

Latest News